[go: up one dir, main page]

EP1474528A4 - METHODS OF DIAGNOSIS OF PROSTATE CANCER, COMPOSITIONS AND METHODS OF EXAMINING PROSTATE CANCER MODULATORS - Google Patents

METHODS OF DIAGNOSIS OF PROSTATE CANCER, COMPOSITIONS AND METHODS OF EXAMINING PROSTATE CANCER MODULATORS

Info

Publication number
EP1474528A4
EP1474528A4 EP01983958A EP01983958A EP1474528A4 EP 1474528 A4 EP1474528 A4 EP 1474528A4 EP 01983958 A EP01983958 A EP 01983958A EP 01983958 A EP01983958 A EP 01983958A EP 1474528 A4 EP1474528 A4 EP 1474528A4
Authority
EP
European Patent Office
Prior art keywords
methods
prostate cancer
diagnosis
compositions
examining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01983958A
Other languages
German (de)
French (fr)
Other versions
EP1474528A2 (en
Inventor
Kurt C Gish
David H Mack
Keith E Wilson
Daniel Afar
Peter Hevezi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Garvan Institute of Medical Research
Cedars Sinai Medical Center
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/847,046 external-priority patent/US20020068036A1/en
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Priority to EP07075380A priority Critical patent/EP1847620A3/en
Publication of EP1474528A2 publication Critical patent/EP1474528A2/en
Publication of EP1474528A4 publication Critical patent/EP1474528A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP01983958A 2000-10-13 2001-10-12 METHODS OF DIAGNOSIS OF PROSTATE CANCER, COMPOSITIONS AND METHODS OF EXAMINING PROSTATE CANCER MODULATORS Withdrawn EP1474528A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07075380A EP1847620A3 (en) 2000-10-13 2001-10-12 Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US687576 1984-12-28
US733288 1985-05-10
US68757600A 2000-10-13 2000-10-13
US73374200A 2000-12-08 2000-12-08
US73328800A 2000-12-08 2000-12-08
US733742 2000-12-08
US26395701P 2001-01-24 2001-01-24
US263957P 2001-01-24
US27679101P 2001-03-16 2001-03-16
US27688801P 2001-03-16 2001-03-16
US276888P 2001-03-16
US276791P 2001-03-16
US28192201P 2001-04-06 2001-04-06
US281922P 2001-04-06
US28621401P 2001-04-24 2001-04-24
US286214P 2001-04-24
US847046 2001-04-30
US09/847,046 US20020068036A1 (en) 2000-10-13 2001-04-30 Novel methods of diagnosis of prostate cancer and/or breast cancer, compositions, and methods of screening for prostate cancer and /or breast cancer modulators
US28858901P 2001-05-04 2001-05-04
US288589P 2001-05-04
PCT/US2001/032045 WO2002030268A2 (en) 2000-10-13 2001-10-12 Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP07075380A Division EP1847620A3 (en) 2000-10-13 2001-10-12 Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer

Publications (2)

Publication Number Publication Date
EP1474528A2 EP1474528A2 (en) 2004-11-10
EP1474528A4 true EP1474528A4 (en) 2006-06-14

Family

ID=27581207

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01983958A Withdrawn EP1474528A4 (en) 2000-10-13 2001-10-12 METHODS OF DIAGNOSIS OF PROSTATE CANCER, COMPOSITIONS AND METHODS OF EXAMINING PROSTATE CANCER MODULATORS

Country Status (6)

Country Link
EP (1) EP1474528A4 (en)
JP (1) JP2005506033A (en)
AU (1) AU2002215345A1 (en)
CA (1) CA2425569A1 (en)
MX (1) MXPA03003151A (en)
WO (1) WO2002030268A2 (en)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69840669D1 (en) 1997-04-10 2009-04-30 Stichting Katholieke Univ PCA3, PCA3 GENES AND METHOD OF USE THEREOF
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
WO1999062941A2 (en) 1998-06-01 1999-12-09 Urogenesys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
DK1222266T3 (en) 1999-09-29 2006-07-10 Diagnocure Inc PCA3 messenger RNA in benign and malignant prostate tissue
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
US20090176722A9 (en) 2000-01-28 2009-07-09 Shiv Srivastava Androgen-regulated PMEPA1 gene and polypeptides
AU2001287639A1 (en) * 2000-07-28 2002-02-13 Ulrich Wissenbach Trp8, trp9 and trp10, markers for cancer
EP1337667A2 (en) 2000-11-16 2003-08-27 Cedars-Sinai Medical Center Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
WO2002055701A2 (en) * 2000-12-15 2002-07-18 Millennium Pharm Inc Human sugar transporter proteins, potassium channel proteins, phospholipid transporter proteins and methods of use thereof
AU2002246708A1 (en) 2000-12-15 2002-08-12 Agensys, Inc. Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer
US20060035237A1 (en) 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
US7118912B2 (en) * 2002-08-26 2006-10-10 Case Western Reserve University Methods and compositions for categorizing patients
US7081516B2 (en) 2002-08-26 2006-07-25 Case Western Reserve University Methods for categorizing patients
CA2439702A1 (en) * 2001-03-05 2002-09-19 Aventis Pharma S.A. Nucleic acids of the human abcc11 gene, vectors containing such nucleic acids and uses thereof
EP2280030A3 (en) 2001-04-10 2011-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
EP2000545B1 (en) 2001-06-20 2011-08-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of lung tumor
US20050272120A1 (en) 2001-06-20 2005-12-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2458915A1 (en) 2001-08-31 2003-03-13 Agensys, Inc. Nucleic acid and corresponding protein entitled 205p1b5 useful in treatment and detection of cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
ES2532757T3 (en) 2001-09-06 2015-03-31 Agensys, Inc. Nucleic acid and corresponding protein called STEAP-1 useful in the treatment and detection of cancer
JP2005519137A (en) * 2001-09-17 2005-06-30 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Methods for using 46828 human acyl-CoA synthetase
US20030100034A1 (en) * 2001-10-16 2003-05-29 Millennium Pharmaceuticals, Inc. 9136, a human aldehyde dehydrogenase family member and uses therefor
WO2003054512A2 (en) * 2001-12-20 2003-07-03 Tularik Inc. Identification of an amplified gene and target for drug intervention
US20030235533A1 (en) * 2002-02-19 2003-12-25 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
WO2005067629A2 (en) * 2004-01-06 2005-07-28 Avalon Pharmaceuticals Cancer-linked genes as targets for chemotherapy
US20040162236A1 (en) * 2002-04-01 2004-08-19 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
CA2485138C (en) * 2002-05-10 2015-04-28 Henry M. Jackson Foundation For The Advancement Of Military Medicine Androgen-regulated pmepa1 gene and methods of using the same to inhibit cancer cell growth
DE10234901A1 (en) * 2002-07-26 2004-02-12 Metagen Pharmaceuticals Gmbh New nucleic acids encoding Mrp4, useful in the diagnosis of prostatic, bladder and ovarian tumors, also in screening for specific binding agents, and potential therapeutic agents
US7408048B2 (en) 2002-08-09 2008-08-05 Melbourne Health Mammalian grainyhead transcription factors
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
WO2004018648A2 (en) * 2002-08-26 2004-03-04 Case Western Reserve University Methods for treating patients and identifying therapeutics
EP1573331A1 (en) * 2002-12-09 2005-09-14 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with phosphodiesterase 9a1 (pde9a1)
JP4824540B2 (en) 2003-02-07 2011-11-30 ダイアノキュアー インク． How to detect prostate cancer in a sample
JP2004357702A (en) * 2003-05-09 2004-12-24 Research Association For Biotechnology New protein and dna encoding the same
US7473531B1 (en) 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
PT2489364E (en) 2003-11-06 2015-04-16 Seattle Genetics Inc Monomethylvaline compounds conjugated to antibodies
WO2005083086A2 (en) * 2004-02-27 2005-09-09 Oncotherapy Science, Inc. Epha4 as therapeutic target of prc and pdaca
PL1742966T3 (en) 2004-04-22 2014-04-30 Agensys Inc Antibodies and molecules derived therefrom that bind to steap-1 proteins
WO2005106488A2 (en) * 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled beta-2 adrenoceptor (adrb2)
EP2286844A3 (en) 2004-06-01 2012-08-22 Genentech, Inc. Antibody-drug conjugates and methods
EP1794314A2 (en) * 2004-07-23 2007-06-13 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 1 (vpac1)
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
ES2579805T3 (en) 2004-09-23 2016-08-16 Genentech, Inc. Antibodies and conjugates engineered with cysteine
EP1817059A2 (en) 2004-12-01 2007-08-15 Genentech, Inc. Conjugates of 1,8-bis-naphthalimides with an antibody
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
WO2006074914A2 (en) * 2005-01-13 2006-07-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Human rna helicase and therapeutic uses thereof
ES2459466T3 (en) 2005-02-25 2014-05-09 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides
RU2639543C9 (en) 2006-10-27 2018-06-14 Дженентек, Инк. Antibodies and immunoconjugates and their applications
WO2008154249A2 (en) * 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2009032292A1 (en) * 2007-09-06 2009-03-12 Case Western Reserve University Methods for diagnosing and treating cancers
JP5589274B2 (en) * 2007-10-25 2014-09-17 東レ株式会社 Immune inducer
DK3106873T3 (en) * 2007-10-25 2019-09-23 Toray Industries METHOD OF DETECTING CANCER
AU2014240339B2 (en) * 2007-10-25 2017-07-13 Toray Industries, Inc. Method for detection of cancer
WO2010009124A2 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
TWI580431B (en) 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 HIG2 and URLC10 epitope peptides and vaccines containing the peptides
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
WO2011031870A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
MA34277B1 (en) 2010-04-15 2013-06-01 Spirogen Developments Sarl PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF
JP2013533732A (en) * 2010-05-03 2013-08-29 ジェネンテック， インコーポレイテッド Compositions and methods for tumor diagnosis and treatment
MX336540B (en) 2010-06-08 2016-01-22 Genentech Inc Cysteine engineered antibodies and conjugates.
CN103313990B (en) 2010-11-17 2016-07-20 基因泰克公司 Alanyl maytansinol antibody coupling matter
KR101992502B1 (en) 2011-05-12 2019-06-24 제넨테크, 인크. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
ES2556584T3 (en) 2011-10-14 2016-01-19 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
DK2906296T3 (en) 2012-10-12 2018-05-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
LT2906253T (en) 2012-10-12 2018-10-10 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
PL2906298T3 (en) 2012-10-12 2019-04-30 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2014057074A1 (en) 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
PT2906251T (en) 2012-10-12 2017-12-04 Medimmune Ltd Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
WO2014057120A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
ES2680153T3 (en) 2012-10-12 2018-09-04 Adc Therapeutics Sa Anti-PSMA-pyrrolobenzodiazepine antibody conjugates
CN110627797A (en) 2012-12-21 2019-12-31 麦迪穆有限责任公司 Asymmetric pyrrolobenzodiazepine dimers for the treatment of proliferative and autoimmune diseases
EA031585B1 (en) 2012-12-21 2019-01-31 Медимьюн Лимитед Pyrrolobenzodiazepines and conjugates thereof
CN105209077B (en) 2013-03-13 2019-06-11 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and its conjugate
CN105142674B (en) 2013-03-13 2018-11-13 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and its conjugate
EA027910B1 (en) 2013-03-13 2017-09-29 Медимьюн Лимитед Pyrrolobenzodiazepines and conjugates thereof
JP2016521966A (en) * 2013-03-15 2016-07-28 メタマーク ジェネティクス， インコーポレイテッド Compositions and methods for cancer prognosis
CN105636612B (en) 2013-08-12 2020-01-14 基因泰克公司 Antibody-drug conjugates and methods of use and treatment
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
BR112016013258A2 (en) 2013-12-16 2018-01-16 Genentech Inc antibody-drug conjugate, pharmaceutical composition, method for treating cancer and kit
CA2928952A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
CN107106700B (en) 2013-12-16 2020-10-30 基因泰克公司 Peptidomimetic compounds and antibody-drug conjugates thereof
US20150252425A1 (en) * 2014-03-05 2015-09-10 Caldera Health Ltd. Gene expression profiling for the diagnosis of prostate cancer
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
TW201625688A (en) 2014-09-12 2016-07-16 建南德克公司 Cysteine engineered antibodies and conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
CN107073136A (en) 2014-09-17 2017-08-18 健泰科生物技术公司 Pyrrolobenzodiazepines Zhuo and its antibody disulphide conjugate
KR20170101895A (en) 2014-11-25 2017-09-06 에이디씨 테라퓨틱스 에스에이 Pyrrolobenzodiazepine-antibody conjugates
CA2969689A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201510684D0 (en) * 2015-06-17 2015-08-05 Almac Diagnostics Ltd Gene signatures predictive of metastatic disease
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 Multiplex Total Antibody and Antibody Conjugated Drug Quantification Assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
CN109313200B (en) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 Bioanalytical methods for characterizing site-specific antibody-drug conjugates
CN109476648B (en) 2016-06-06 2022-09-13 豪夫迈·罗氏有限公司 Sevelamer antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
CN110139674B (en) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 Method for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
CA3047683C (en) 2017-02-08 2020-03-10 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
SG11201909218RA (en) 2017-04-03 2019-11-28 Hoffmann La Roche Antibodies binding to steap-1
AU2018255876B2 (en) 2017-04-18 2020-04-30 Medimmune Limited Pyrrolobenzodiazepine conjugates
US20200129637A1 (en) 2017-04-20 2020-04-30 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
UA127900C2 (en) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Dosage regimes for the administration of an anti-cd19 adc
EP3668874B1 (en) 2017-08-18 2021-12-22 Medimmune Limited Pyrrolobenzodiazepine conjugates
AU2018337815A1 (en) 2017-09-20 2020-03-12 Ph Pharma Co., Ltd. Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2020010305A1 (en) * 2018-07-05 2020-01-09 The Board Of Regents Of The University Of Oklahoma Gene signatures for cancer characterization and methods of use
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CN113056287A (en) 2018-10-24 2021-06-29 豪夫迈·罗氏有限公司 Conjugated chemical degradation inducers and methods of use
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
BR112021018260A2 (en) 2019-03-15 2021-11-23 Medimmune Ltd Azetidobenzodiazepine dimers and conjugates comprising the same for use in the treatment of cancer
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
TW202432187A (en) 2022-12-23 2024-08-16 美商建南德克公司 Cereblon degrader conjugates, and uses thereof
WO2024220546A2 (en) 2023-04-17 2024-10-24 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
CN119215114A (en) * 2024-12-03 2024-12-31 浙江理工大学 Application of lily extracellular vesicles in preparing tumor therapeutic drugs

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028498A1 (en) * 1994-04-15 1995-10-26 The Trustees Of Columbia University In The City Of New York Method for molecular staging of prostate cancer
US5858673A (en) * 1996-06-24 1999-01-12 Charlotte-Mecklenburg Hospital Authority Method for detecting prostate cells
WO1999037811A1 (en) * 1998-01-21 1999-07-29 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
WO1999042622A1 (en) * 1998-02-23 1999-08-26 Dana-Farber Cancer Institute, Inc. Method for identifying mismatch repair glycosylase reactive sites, compound and uses thereof_____________________________________
WO1999064594A2 (en) * 1998-06-11 1999-12-16 Chiron Corporation Genes and gene expression products that are differentially regulated in prostate cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001241408A1 (en) * 2000-01-31 2001-08-07 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001060860A2 (en) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028498A1 (en) * 1994-04-15 1995-10-26 The Trustees Of Columbia University In The City Of New York Method for molecular staging of prostate cancer
US5858673A (en) * 1996-06-24 1999-01-12 Charlotte-Mecklenburg Hospital Authority Method for detecting prostate cells
WO1999037811A1 (en) * 1998-01-21 1999-07-29 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
WO1999042622A1 (en) * 1998-02-23 1999-08-26 Dana-Farber Cancer Institute, Inc. Method for identifying mismatch repair glycosylase reactive sites, compound and uses thereof_____________________________________
WO1999064594A2 (en) * 1998-06-11 1999-12-16 Chiron Corporation Genes and gene expression products that are differentially regulated in prostate cancer

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CARLISLE A J ET AL: "Development of a prostate cDNA microarray and statistical gene expression analysis package", MOLECULAR CARCINOGENESIS, ALAN LISS, NEW YORK, NY,, US, vol. 28, no. 1, May 2000 (2000-05-01), pages 12 - 22, XP002225396, ISSN: 0899-1987 *
DATABASE EMBL [online] 21 November 1996 (1996-11-21), "zk91c02.s1 Soares_pregnant_uterus_NbHPU Homo sapiens cDNA clone IMAGE:490178 3', mRNA sequence.", XP002339482, retrieved from EBI accession no. EM_HUM:HSAA21266 Database accession no. HSAA21266 *
DATABASE NETAFFX [online] Affymetrix; 12 April 2006 (2006-04-12), XP002376990, retrieved from HTTPS://WWW.AFFYMETRIX.COM/ANALYSIS/NETAFFX/FULLRECORD.AFFX?PK=HUGENEFL%3AU41060_AT *
ELEK J ET AL: "MICROARRAY-BASED EXPRESSION PROFILING IN PROSTATE TUMORS", IN VIVO - INTERNATIONAL JOURNAL OF IN VIVO RESEARCH, GB, vol. 14, no. 1, January 2000 (2000-01-01), pages 173 - 182, XP001027452, ISSN: 0258-851X *
GREEN C ET AL: "Human Breast Cancer, estrogen regulated LIV-1 protein (LIV-1) mRNA, partial cds", ENTREZ NUCLEOTIDE, 6 April 1996 (1996-04-06), XP002175106 *
LADEANA HILLIER ET AL: "Generation and analysis of 280,000 human expressed sequence tags", PCR METHODS AND APPLICATIONS, COLD SPRING HARBOR, NY, US, vol. 6, no. 9, September 1996 (1996-09-01), pages 807 - 828, XP002140684, ISSN: 1054-9803 *
XU JIANGCHUN ET AL: "Identification of differentially expressed genes in human prostate cancer using subtraction and microarray", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 6, 15 March 2000 (2000-03-15), pages 1677 - 1682, XP002198982, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
JP2005506033A (en) 2005-03-03
CA2425569A1 (en) 2002-04-18
MXPA03003151A (en) 2003-08-19
EP1474528A2 (en) 2004-11-10
AU2002215345A1 (en) 2002-04-22
WO2002030268A2 (en) 2002-04-18
WO2002030268A3 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
EP1474528A4 (en) METHODS OF DIAGNOSIS OF PROSTATE CANCER, COMPOSITIONS AND METHODS OF EXAMINING PROSTATE CANCER MODULATORS
WO2002040634A3 (en) Expression miniarrays and uses thereof
DE60233157D1 (en) TWO-CHAMBER PACEMAKER SYSTEM FOR THE DIAGNOSIS AND REMEDY OF ARRHYTHMIES
EP1257287A4 (en) COMPOUNDS AND METHODS FOR EARLY DIAGNOSIS OF EGG CANCER
DE60210880D1 (en) Combined bipolar forceps and scissors instrument
NO20023402D0 (en) Mixtures and Methods for the Treatment and Diagnosis of Prostate Cancer
NO20010196D0 (en) Compositions and Methods for Therapy and Diagnosis of Prostate Cancer
DE59900101D1 (en) Medical instrument for tissue preparation
NO20016427D0 (en) Compositions and Methods for the Treatment of Diagnosis of Lung Cancer
YU37304A (en) Specific binding agents of human angiopoietin-2
DE60115874D1 (en) INSTRUMENT FOR SURGICAL TREATMENT
DE69932191D1 (en) Device for the examination of body fluid
DE59912963D1 (en) MEDICAL INSTRUMENT FOR PREPARING TISSUE
EP1516049A4 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF LUNG CANCER
EP1446013A4 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF LUNG CANCER
DE60032784D1 (en) MARKER PROTEINS FOR PROSTATE CANCER
DE60001555D1 (en) AQUEOUS SOLUTION FOR PRESERVING TISSUE AND ORGANS
AU2002339439A1 (en) Use of heparin-binding domain of fibronectin for diagnosis and treatment of cancer
ATE259379T1 (en) FLUORESCEIN ISOTHIOCYANATE (FITC) SINISTRINE, ITS PREPARATION AND USE
PL366066A1 (en) Compositions and methods of treatment and diagnosis of breast cancer
DE60221115D1 (en) COMPOSITIONS AND METHODS FOR USE OF FIBRONECTIN FRAGMENTS IN CANCER DIAGNOSIS
DE50104761D1 (en) MEASURING ARRANGEMENT FOR THE INVESTIGATION OF A TISSUE SECTION OF A PATIENT
DE60119731D1 (en) IMMUNOLOGICAL TEST AND SET FOR THE DIAGNOSIS OF PROSTATADENO CARCINOMA
DE60134158D1 (en) COMPOSITIONS AND METHODS FOR THERAPY AND DIAGNOSIS OF LUNG CANCER
DE69938729D1 (en) METHOD FOR DIAGNOSIS OF BONE MEASURES FROM MALIGNANT TUMORS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030428

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20060517

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GARVAN INSTITUTE OF MEDICAL RESEARCH

17Q First examination report despatched

Effective date: 20061103

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CEDARS-SINAI MEDICAL CENTER

Owner name: GARVAN INSTITUTE OF MEDICAL RESEARCH

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ANGUS, DAVID B.

Inventor name: HEVEZI, PETER

Inventor name: AFAR, DANIEL

Inventor name: WILSON, KEITH, E.

Inventor name: MACK, DAVID, H.

Inventor name: GISH, KURT, C.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070914